Multiple Myeloma and Plasma Cell Neoplasm
Conditions
Keywords
stage I multiple myeloma, stage II multiple myeloma, stage III multiple myeloma, refractory multiple myeloma
Brief summary
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at DNA samples from patients with multiple myeloma.
Detailed description
OBJECTIVES: * Determine whether there is an increased frequency of 1 or more polymorphic alleles that are associated with clinical endpoints using custom myeloma single nucleotide polymorphism (SNP) chip analysis of banked DNA samples from patients with multiple myeloma. * Determine SNPs associated with toxicities caused, not by variations in tumor cell genetics, but by individual genetic variations affecting drug activation, distribution, metabolism, and export (ADME). * Determine SNPs associated with response, influenced by the same ADME. * Determine SNPs associated with bone disease (as a variable) among patients with multiple myeloma. * Determine SNPs associated with epidemiology (i.e., risk factors for the development of multiple myeloma). OUTLINE: This is a retrospective, multicenter study. Banked DNA samples are analyzed using a custom single nucleotide polymorphism (SNP) chip to assess approximately 3,590 SNPs from 1,061 genes that are associated with myeloma growth and response. PROJECTED ACCRUAL: A total of 600 patients will be accrued for this study.
Interventions
GENETICpolymorphism analysis
Sponsors
National Cancer Institute (NCI)
ECOG-ACRIN Cancer Research Group
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of multiple myeloma * DNA samples banked from other ECOG studies (and other clinical trial groups \[e.g., SWOG and MRC\]) PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Increased frequency of ≥1 polymorphic alleles associated with clinical endpoints using custom myeloma SNP chip analysis of banked DNA samples from patients with multiple myeloma | 1 month |
| SNPs associated with toxicities caused by individual genetic variations affecting drug activation, distribution, metabolism, and export (ADME) | 1 month |
| SNPs associated with response | 1 month |
| SNPs associated with bone disease | 1 month |
| SNPs associated with epidemiology (i.e., risk factors for the development of multiple myeloma) | 1 month |
Outcome results
None listed